ArriVent BioPharma, Ebitda Over Time
| AVBP Stock | 29.11 0.37 1.29% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out ArriVent BioPharma, Performance and ArriVent BioPharma, Correlation. ArriVent |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ArriVent BioPharma,. If investors know ArriVent will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ArriVent BioPharma, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.61) | Return On Assets (0.21) | Return On Equity (0.31) |
The market value of ArriVent BioPharma, is measured differently than its book value, which is the value of ArriVent that is recorded on the company's balance sheet. Investors also form their own opinion of ArriVent BioPharma,'s value that differs from its market value or its book value, called intrinsic value, which is ArriVent BioPharma,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ArriVent BioPharma,'s market value can be influenced by many factors that don't directly affect ArriVent BioPharma,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ArriVent BioPharma,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if ArriVent BioPharma, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ArriVent BioPharma,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Ebitda Analysis
Compare ArriVent BioPharma, and related stocks such as WiMi Hologram Cloud, Anterix, and NETGEAR Ebitda Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| WIMI | 90.7 M | 90.7 M | 90.7 M | 90.7 M | 90.7 M | 90.7 M | 90.7 M | 90.7 M | 115.7 M | 130.4 M | (135.7 M) | (228.4 M) | (308.7 M) | (509.6 M) | (484.1 M) |
| ATEX | (962.4 K) | (962.4 K) | (962.4 K) | (827 K) | (14 M) | (21.3 M) | (30.5 M) | (28.2 M) | (28.1 M) | (33.2 M) | (47.3 M) | (46.5 M) | (53.4 M) | (51.6 M) | (49 M) |
| NTGR | (170.6 M) | 129.8 M | 129.3 M | 118.4 M | 178.8 M | 92.8 M | 121.9 M | 87.1 M | 45 M | 26.2 M | 94.5 M | 80.5 M | (23.8 M) | (33.3 M) | (31.6 M) |
| MOS | 267.8 M | 3.8 B | 3.1 B | 2.8 B | 2.1 B | 2 B | 1.1 B | 1.2 B | 909.5 M | 368.7 M | 412.9 M | 3.3 B | 4.8 B | 2.6 B | 1.4 B |
| SCL | 18.8 M | 165.6 M | 180 M | 162.4 M | 151 M | 186.9 M | 203.2 M | 231.8 M | 231.8 M | 199.4 M | 235.7 M | 265.3 M | 304 M | 169.7 M | 122.8 M |
| ECVT | 94.8 M | 94.8 M | 94.8 M | 94.8 M | 94.8 M | 94.8 M | 198.9 M | 294.6 M | 386.3 M | 417.9 M | 136.3 M | 130.7 M | 199.5 M | 234 M | 186 M |
| HWKN | 2.7 M | 43.6 M | 35.6 M | 40.7 M | 43.4 M | 46.7 M | 59.6 M | 49.8 M | 58.6 M | 63.1 M | 80 M | 95.5 M | 117.2 M | 137.2 M | 144.1 M |
ArriVent BioPharma, and related stocks such as WiMi Hologram Cloud, Anterix, and NETGEAR Ebitda description
My Equities
My Current Equities and Potential Positions
| ArriVent BioPharma, Common | AVBP |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Location | Pennsylvania; U.S.A |
| Exchange | NASDAQ Exchange |
null 29.11
Additional Tools for ArriVent Stock Analysis
When running ArriVent BioPharma,'s price analysis, check to measure ArriVent BioPharma,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ArriVent BioPharma, is operating at the current time. Most of ArriVent BioPharma,'s value examination focuses on studying past and present price action to predict the probability of ArriVent BioPharma,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ArriVent BioPharma,'s price. Additionally, you may evaluate how the addition of ArriVent BioPharma, to your portfolios can decrease your overall portfolio volatility.